ARCHIVES

Also FDA clarifies data requirements for phase I IND applications.

This article is from The Cancer Letter archive.

Vol. 31 No. 17 | April 29, 2005

Download PDF Visit The Full Archive

Related Articles

Study Validates “PEM” Scans As Biopsy Guidance Method

April 29, 2011

Lenalidomide, An Altered Thalidomide, Shows Promise

November 24, 2006

DRCCA Bard Group Recommends No New Nationwide Screening Program Until More Research Is Done

November 5, 1982

In Brief: NCI Monograph On Year 2000 Objectives Now Available; Radiation Accident Workshop Planned

October 31, 1986

DCBD Board Okays Recombinant DNA Diagnosis Concept, Two Others, But Rejects Three

June 3, 1983

Breast Density As Important As Age In Determining Risk

September 29, 2006